Ironwood Pharmaceuticals
formerly Ironwood PharmaIPOLeaders in GI Health Innovation
Public · Boston, United States · Founded 1998 · $175.0M raised
- Headquarters
- Boston, Massachusetts
- Employees
- 201–500
- Founded
- 1998
- Business Model
- B2B
- Website
- ironwoodpharma.com
- Total Funding
- $175.0M
- Last Round
- $175.0M Corporate RoundFeb 2019
- Rounds
- 1
- Type
- Public
About
Ironwood Pharmaceuticals is a pioneering GI-focused biopharmaceutical company dedicated to advancing treatments for gastrointestinal diseases. Best known as originator of linaclotide (marketed as LINZESS), the US market leader for IBS-C and chronic idiopathic constipation. In 2023 the FDA approved LINZESS for pediatric functional constipation. Ironwood partners with AbbVie on US commercialization.
Summary
Ironwood Pharmaceuticals is a Biotech company based in Boston, United States, founded in 1998. It has raised $175.0M in total across 1 round, most recently a $175.0M Corporate Round round in Feb 2019.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Feb 2019
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Similar Companies
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
BridgeBio makes targeted treatments for genetic diseases.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...